<table id="ID69" width="101%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Incidence of Primary Endpoint Events</caption>
<col span="1" width="37%"></col>
<col span="1" width="11%"></col>
<col span="1" width="10%"></col>
<col span="1" width="17%"></col>
<col span="1" width="18%"></col>
<col span="1" width="8%"></col>
<tbody>
<tr>
<td>
<br/>
</td>
<td>Incidence<br/>
</td>
<td>Risk Reduction<br/>
</td>
<td>95 % C.l.<br/>
</td>
<td>p-Value<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>Losartan<br/>
</td>
<td>Placebo<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Primary Composite Endpoint<br/>
</td>
<td>43.5%<br/>
</td>
<td>47.1%<br/>
</td>
<td>16.1%<br/>
</td>
<td>2.3% to 27.9%<br/>
</td>
<td>0.022<br/>
</td>
</tr>
<tr>
<td>         Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event<br/>
</td>
</tr>
<tr>
<td>         Doubling of Serum Creatinine<br/>
</td>
<td>21.6%<br/>
</td>
<td>26.0%<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>         ESRD<br/>
</td>
<td>8.5%<br/>
</td>
<td>8.5%<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>         Death<br/>
</td>
<td>13.4%<br/>
</td>
<td>12.6%<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Overall Incidence of Doubling of Serum Creatinine, ESRD and Death<br/>
</td>
</tr>
<tr>
<td>Doubling of Serum Creatinine<br/>
</td>
<td>21.6%<br/>
</td>
<td>26.0%<br/>
</td>
<td>25.3%<br/>
</td>
<td>7.8% to 39.4%<br/>
</td>
<td>0.006<br/>
</td>
</tr>
<tr>
<td>ESRD<br/>
</td>
<td>19.6%<br/>
</td>
<td>25.5%<br/>
</td>
<td>28.6%<br/>
</td>
<td>11.5% to 42.4%<br/>
</td>
<td>0.002<br/>
</td>
</tr>
<tr>
<td>Death<br/>
</td>
<td>21.0%<br/>
</td>
<td>20.3%<br/>
</td>
<td>-1.7%<br/>
</td>
<td>-26.9% to 18.6%<br/>
</td>
<td>0.884<br/>
</td>
</tr>
</tbody>
</table>